Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Gilead Sciences Inc (GILD) Common Stock USD0.001

Sell:$64.55 Buy:$64.57 Change: $0.26 (0.41%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$64.55
Buy:$64.57
Change: $0.26 (0.41%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$64.55
Buy:$64.57
Change: $0.26 (0.41%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Contact details

Address:
333 LAKESIDE DR
FOSTER CITY
94404
United States
Telephone:
+1 (650) 5743000
Website:
https://www.gilead.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GILD
ISIN:
US3755581036
Market cap:
$79.45 billion
Shares in issue:
1.26 billion
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Daniel O'Day
    Chairman of the Board, Chief Executive Officer
  • Andrew Dickinson
    Chief Financial Officer, Executive Vice President
  • Brett Pletcher
    Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
  • Jyoti Mehra
    Executive Vice President of Human Resources
  • Linda Higgins
    Senior Vice President - Head of External Innovation
  • Michael Quigley
    Senior Vice President - Research Biology
  • Johanna Mercier
    Chief Commercial Officer
  • Merdad Parsey
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.